HIV-Specific Granzyme B-Secreting but Not Gamma Interferon-Secreting T Cells Are Associated with Reduced Viral Reservoirs in Early HIV Infection
A major barrier to a human immunodeficiency virus type 1 (HIV-1) infection cure is the establishment of a viral reservoir in spite of combined antiretroviral therapy (cART). It is unclear how HIV-specific cytotoxic T lymphocytes (CTLs) influence the size of the reservoir in early HIV infection. Twen...
Saved in:
Published in | Journal of virology Vol. 91; no. 8 |
---|---|
Main Authors | , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
American Society for Microbiology
15.04.2017
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | A major barrier to a human immunodeficiency virus type 1 (HIV-1) infection cure is the establishment of a viral reservoir in spite of combined antiretroviral therapy (cART). It is unclear how HIV-specific cytotoxic T lymphocytes (CTLs) influence the size of the reservoir in early HIV infection. Twenty-eight subjects with early HIV infection were recruited to receive cART and followed for 48 weeks. HIV reservoirs in peripheral CD4
T cells measured by cell-associated proviral DNA and viral outgrowth cultures were determined at baseline and after 48 weeks of cART. At baseline, granzyme B and gamma interferon (IFN-γ) enzyme-linked immunosorbent spot (ELISpot) assays were performed with peptides spanning the HIV proteome. All subjects had detectable HIV-specific granzyme B and IFN-γ responses at baseline. The quantity and specificity of granzyme B responses did not correlate with IFN-γ responses. For granzyme B, Tat/Rev was the most dominant whereas for IFN-γ, Gag predominated. HIV-specific granzyme B T cell responses negatively correlated with HIV proviral loads at baseline and at 48 weeks and with replication-competent viral infectious units per million (IUPM) CD4
T cells at baseline but not significantly at 48 weeks. Tat/Rev-, Env-, Gag-, and Vif-specific granzyme B responses correlated most strongly with reservoir control. There was no correlation of HIV-specific IFN-γ responses with reservoir size at baseline or at 48 weeks. The majority of granzyme B responses were contributed by CD8
T cells. Thus, our findings suggest that the induction of potent granzyme B-producing CTLs to Tat, Rev, Env, Gag, and Vif during early infection may be able to prevent the establishment of a large viral reservoir, thereby facilitating a reduced HIV burden.
A major barrier to the cure of human immunodeficiency virus type 1 (HIV-1) infection is the establishment of a viral reservoir that must be significantly reduced or eradicated entirely to enable a cure. Combined antiretroviral therapy (cART) alone is unable to clear this viral reservoir. It has been shown that CD8
cytotoxic T lymphocytes (CTLs) are important in controlling early HIV infection by reducing plasma viremia. However, it is not known if these HIV-specific CTLs influence the establishment of the viral reservoir in early HIV infection. We show that HIV-specific granzyme B responses targeting HIV Tat/Rev, Env, Gag, and Vif, but not IFN-γ responses, are associated with reduced virus reservoirs at baseline and at 48 weeks of cART. These findings shed light on the nature of the effector CTL response that might limit reservoir size with implications for cure research and HIV vaccines. |
---|---|
AbstractList | A major barrier to a human immunodeficiency virus type 1 (HIV-1) infection cure is the establishment of a viral reservoir in spite of combined antiretroviral therapy (cART). It is unclear how HIV-specific cytotoxic T lymphocytes (CTLs) influence the size of the reservoir in early HIV infection. Twenty-eight subjects with early HIV infection were recruited to receive cART and followed for 48 weeks. HIV reservoirs in peripheral CD4
+
T cells measured by cell-associated proviral DNA and viral outgrowth cultures were determined at baseline and after 48 weeks of cART. At baseline, granzyme B and gamma interferon (IFN-γ) enzyme-linked immunosorbent spot (ELISpot) assays were performed with peptides spanning the HIV proteome. All subjects had detectable HIV-specific granzyme B and IFN-γ responses at baseline. The quantity and specificity of granzyme B responses did not correlate with IFN-γ responses. For granzyme B, Tat/Rev was the most dominant whereas for IFN-γ, Gag predominated. HIV-specific granzyme B T cell responses negatively correlated with HIV proviral loads at baseline and at 48 weeks and with replication-competent viral infectious units per million (IUPM) CD4
+
T cells at baseline but not significantly at 48 weeks. Tat/Rev-, Env-, Gag-, and Vif-specific granzyme B responses correlated most strongly with reservoir control. There was no correlation of HIV-specific IFN-γ responses with reservoir size at baseline or at 48 weeks. The majority of granzyme B responses were contributed by CD8
+
T cells. Thus, our findings suggest that the induction of potent granzyme B-producing CTLs to Tat, Rev, Env, Gag, and Vif during early infection may be able to prevent the establishment of a large viral reservoir, thereby facilitating a reduced HIV burden.
IMPORTANCE
A major barrier to the cure of human immunodeficiency virus type 1 (HIV-1) infection is the establishment of a viral reservoir that must be significantly reduced or eradicated entirely to enable a cure. Combined antiretroviral therapy (cART) alone is unable to clear this viral reservoir. It has been shown that CD8
+
cytotoxic T lymphocytes (CTLs) are important in controlling early HIV infection by reducing plasma viremia. However, it is not known if these HIV-specific CTLs influence the establishment of the viral reservoir in early HIV infection. We show that HIV-specific granzyme B responses targeting HIV Tat/Rev, Env, Gag, and Vif, but not IFN-γ responses, are associated with reduced virus reservoirs at baseline and at 48 weeks of cART. These findings shed light on the nature of the effector CTL response that might limit reservoir size with implications for cure research and HIV vaccines. A major barrier to a human immunodeficiency virus type 1 (HIV-1) infection cure is the establishment of a viral reservoir in spite of combined antiretroviral therapy (cART). It is unclear how HIV-specific cytotoxic T lymphocytes (CTLs) influence the size of the reservoir in early HIV infection. Twenty-eight subjects with early HIV infection were recruited to receive cART and followed for 48 weeks. HIV reservoirs in peripheral CD4+ T cells measured by cell-associated proviral DNA and viral outgrowth cultures were determined at baseline and after 48 weeks of cART. At baseline, granzyme B and gamma interferon (IFN-γ) enzyme-linked immunosorbent spot (ELISpot) assays were performed with peptides spanning the HIV proteome. All subjects had detectable HIV-specific granzyme B and IFN-γ responses at baseline. The quantity and specificity of granzyme B responses did not correlate with IFN-γ responses. For granzyme B, Tat/Rev was the most dominant whereas for IFN-γ, Gag predominated. HIV-specific granzyme B T cell responses negatively correlated with HIV proviral loads at baseline and at 48 weeks and with replication-competent viral infectious units per million (IUPM) CD4+ T cells at baseline but not significantly at 48 weeks. Tat/Rev-, Env-, Gag-, and Vif-specific granzyme B responses correlated most strongly with reservoir control. There was no correlation of HIV-specific IFN-γ responses with reservoir size at baseline or at 48 weeks. The majority of granzyme B responses were contributed by CD8+ T cells. Thus, our findings suggest that the induction of potent granzyme B-producing CTLs to Tat, Rev, Env, Gag, and Vif during early infection may be able to prevent the establishment of a large viral reservoir, thereby facilitating a reduced HIV burden.IMPORTANCE A major barrier to the cure of human immunodeficiency virus type 1 (HIV-1) infection is the establishment of a viral reservoir that must be significantly reduced or eradicated entirely to enable a cure. Combined antiretroviral therapy (cART) alone is unable to clear this viral reservoir. It has been shown that CD8+ cytotoxic T lymphocytes (CTLs) are important in controlling early HIV infection by reducing plasma viremia. However, it is not known if these HIV-specific CTLs influence the establishment of the viral reservoir in early HIV infection. We show that HIV-specific granzyme B responses targeting HIV Tat/Rev, Env, Gag, and Vif, but not IFN-γ responses, are associated with reduced virus reservoirs at baseline and at 48 weeks of cART. These findings shed light on the nature of the effector CTL response that might limit reservoir size with implications for cure research and HIV vaccines. ABSTRACT A major barrier to a human immunodeficiency virus type 1 (HIV-1) infection cure is the establishment of a viral reservoir in spite of combined antiretroviral therapy (cART). It is unclear how HIV-specific cytotoxic T lymphocytes (CTLs) influence the size of the reservoir in early HIV infection. Twenty-eight subjects with early HIV infection were recruited to receive cART and followed for 48 weeks. HIV reservoirs in peripheral CD4 + T cells measured by cell-associated proviral DNA and viral outgrowth cultures were determined at baseline and after 48 weeks of cART. At baseline, granzyme B and gamma interferon (IFN-γ) enzyme-linked immunosorbent spot (ELISpot) assays were performed with peptides spanning the HIV proteome. All subjects had detectable HIV-specific granzyme B and IFN-γ responses at baseline. The quantity and specificity of granzyme B responses did not correlate with IFN-γ responses. For granzyme B, Tat/Rev was the most dominant whereas for IFN-γ, Gag predominated. HIV-specific granzyme B T cell responses negatively correlated with HIV proviral loads at baseline and at 48 weeks and with replication-competent viral infectious units per million (IUPM) CD4 + T cells at baseline but not significantly at 48 weeks. Tat/Rev-, Env-, Gag-, and Vif-specific granzyme B responses correlated most strongly with reservoir control. There was no correlation of HIV-specific IFN-γ responses with reservoir size at baseline or at 48 weeks. The majority of granzyme B responses were contributed by CD8 + T cells. Thus, our findings suggest that the induction of potent granzyme B-producing CTLs to Tat, Rev, Env, Gag, and Vif during early infection may be able to prevent the establishment of a large viral reservoir, thereby facilitating a reduced HIV burden. IMPORTANCE A major barrier to the cure of human immunodeficiency virus type 1 (HIV-1) infection is the establishment of a viral reservoir that must be significantly reduced or eradicated entirely to enable a cure. Combined antiretroviral therapy (cART) alone is unable to clear this viral reservoir. It has been shown that CD8 + cytotoxic T lymphocytes (CTLs) are important in controlling early HIV infection by reducing plasma viremia. However, it is not known if these HIV-specific CTLs influence the establishment of the viral reservoir in early HIV infection. We show that HIV-specific granzyme B responses targeting HIV Tat/Rev, Env, Gag, and Vif, but not IFN-γ responses, are associated with reduced virus reservoirs at baseline and at 48 weeks of cART. These findings shed light on the nature of the effector CTL response that might limit reservoir size with implications for cure research and HIV vaccines. A major barrier to a human immunodeficiency virus type 1 (HIV-1) infection cure is the establishment of a viral reservoir in spite of combined antiretroviral therapy (cART). It is unclear how HIV-specific cytotoxic T lymphocytes (CTLs) influence the size of the reservoir in early HIV infection. Twenty-eight subjects with early HIV infection were recruited to receive cART and followed for 48 weeks. HIV reservoirs in peripheral CD4 T cells measured by cell-associated proviral DNA and viral outgrowth cultures were determined at baseline and after 48 weeks of cART. At baseline, granzyme B and gamma interferon (IFN-γ) enzyme-linked immunosorbent spot (ELISpot) assays were performed with peptides spanning the HIV proteome. All subjects had detectable HIV-specific granzyme B and IFN-γ responses at baseline. The quantity and specificity of granzyme B responses did not correlate with IFN-γ responses. For granzyme B, Tat/Rev was the most dominant whereas for IFN-γ, Gag predominated. HIV-specific granzyme B T cell responses negatively correlated with HIV proviral loads at baseline and at 48 weeks and with replication-competent viral infectious units per million (IUPM) CD4 T cells at baseline but not significantly at 48 weeks. Tat/Rev-, Env-, Gag-, and Vif-specific granzyme B responses correlated most strongly with reservoir control. There was no correlation of HIV-specific IFN-γ responses with reservoir size at baseline or at 48 weeks. The majority of granzyme B responses were contributed by CD8 T cells. Thus, our findings suggest that the induction of potent granzyme B-producing CTLs to Tat, Rev, Env, Gag, and Vif during early infection may be able to prevent the establishment of a large viral reservoir, thereby facilitating a reduced HIV burden. A major barrier to the cure of human immunodeficiency virus type 1 (HIV-1) infection is the establishment of a viral reservoir that must be significantly reduced or eradicated entirely to enable a cure. Combined antiretroviral therapy (cART) alone is unable to clear this viral reservoir. It has been shown that CD8 cytotoxic T lymphocytes (CTLs) are important in controlling early HIV infection by reducing plasma viremia. However, it is not known if these HIV-specific CTLs influence the establishment of the viral reservoir in early HIV infection. We show that HIV-specific granzyme B responses targeting HIV Tat/Rev, Env, Gag, and Vif, but not IFN-γ responses, are associated with reduced virus reservoirs at baseline and at 48 weeks of cART. These findings shed light on the nature of the effector CTL response that might limit reservoir size with implications for cure research and HIV vaccines. A major barrier to a human immunodeficiency virus type 1 (HIV-1) infection cure is the establishment of a viral reservoir in spite of combined antiretroviral therapy (cART). It is unclear how HIV-specific cytotoxic T lymphocytes (CTLs) influence the size of the reservoir in early HIV infection. Twenty-eight subjects with early HIV infection were recruited to receive cART and followed for 48 weeks. HIV reservoirs in peripheral CD4+ T cells measured by cell-associated proviral DNA and viral outgrowth cultures were determined at baseline and after 48 weeks of cART. At baseline, granzyme B and gamma interferon (IFN- gamma ) enzyme-linked immunosorbent spot (ELISpot) assays were performed with peptides spanning the HIV proteome. All subjects had detectable HIV-specific granzyme B and IFN- gamma responses at baseline. The quantity and specificity of granzyme B responses did not correlate with IFN- gamma responses. For granzyme B, Tat/Rev was the most dominant whereas for IFN- gamma , Gag predominated. HIV-specific granzyme B T cell responses negatively correlated with HIV proviral loads at baseline and at 48 weeks and with replication-competent viral infectious units per million (IUPM) CD4+ T cells at baseline but not significantly at 48 weeks. Tat/Rev-, Env-, Gag-, and Vif-specific granzyme B responses correlated most strongly with reservoir control. There was no correlation of HIV-specific IFN- gamma responses with reservoir size at baseline or at 48 weeks. The majority of granzyme B responses were contributed by CD8+ T cells. Thus, our findings suggest that the induction of potent granzyme B-producing CTLs to Tat, Rev, Env, Gag, and Vif during early infection may be able to prevent the establishment of a large viral reservoir, thereby facilitating a reduced HIV burden. IMPORTANCE A major barrier to the cure of human immunodeficiency virus type 1 (HIV-1) infection is the establishment of a viral reservoir that must be significantly reduced or eradicated entirely to enable a cure. Combined antiretroviral therapy (cART) alone is unable to clear this viral reservoir. It has been shown that CD8+ cytotoxic T lymphocytes (CTLs) are important in controlling early HIV infection by reducing plasma viremia. However, it is not known if these HIV-specific CTLs influence the establishment of the viral reservoir in early HIV infection. We show that HIV-specific granzyme B responses targeting HIV Tat/Rev, Env, Gag, and Vif, but not IFN- gamma responses, are associated with reduced virus reservoirs at baseline and at 48 weeks of cART. These findings shed light on the nature of the effector CTL response that might limit reservoir size with implications for cure research and HIV vaccines. |
Author | Cohen, Jared C Kovacs, Colin Ostrowski, Mario Khozin, Alexandra Liu, Daheng Hundal, Sabrina Ho, Mu Bonner, Phil Benko, Erika Rahman, A K M Nur-Ur Saiyed, Aamir Yue, Feng Yun Liu, Jun Mujib, Shariq |
Author_xml | – sequence: 1 givenname: Feng Yun surname: Yue fullname: Yue, Feng Yun organization: Departments of Medicine and Immunology, University of Toronto, Toronto, Ontario, Canada – sequence: 2 givenname: Jared C surname: Cohen fullname: Cohen, Jared C organization: Keenan Research Centre for Biomedical Science of Saint Michael's Hospital, Toronto, Ontario, Canada – sequence: 3 givenname: Mu surname: Ho fullname: Ho, Mu organization: Departments of Medicine and Immunology, University of Toronto, Toronto, Ontario, Canada – sequence: 4 givenname: A K M Nur-Ur surname: Rahman fullname: Rahman, A K M Nur-Ur organization: Departments of Medicine and Immunology, University of Toronto, Toronto, Ontario, Canada – sequence: 5 givenname: Jun surname: Liu fullname: Liu, Jun organization: Departments of Medicine and Immunology, University of Toronto, Toronto, Ontario, Canada – sequence: 6 givenname: Shariq surname: Mujib fullname: Mujib, Shariq organization: Departments of Medicine and Immunology, University of Toronto, Toronto, Ontario, Canada – sequence: 7 givenname: Aamir surname: Saiyed fullname: Saiyed, Aamir organization: Departments of Medicine and Immunology, University of Toronto, Toronto, Ontario, Canada – sequence: 8 givenname: Sabrina surname: Hundal fullname: Hundal, Sabrina organization: Departments of Medicine and Immunology, University of Toronto, Toronto, Ontario, Canada – sequence: 9 givenname: Alexandra surname: Khozin fullname: Khozin, Alexandra organization: Departments of Medicine and Immunology, University of Toronto, Toronto, Ontario, Canada – sequence: 10 givenname: Phil surname: Bonner fullname: Bonner, Phil organization: Departments of Medicine and Immunology, University of Toronto, Toronto, Ontario, Canada – sequence: 11 givenname: Daheng surname: Liu fullname: Liu, Daheng organization: Departments of Medicine and Immunology, University of Toronto, Toronto, Ontario, Canada – sequence: 12 givenname: Erika surname: Benko fullname: Benko, Erika organization: Maple Leaf Clinic, Toronto, Ontario, Canada – sequence: 13 givenname: Colin surname: Kovacs fullname: Kovacs, Colin organization: Maple Leaf Clinic, Toronto, Ontario, Canada – sequence: 14 givenname: Mario surname: Ostrowski fullname: Ostrowski, Mario email: mario.ostrowski@gmail.com organization: Keenan Research Centre for Biomedical Science of Saint Michael's Hospital, Toronto, Ontario, Canada |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/28179527$$D View this record in MEDLINE/PubMed |
BookMark | eNqNkUFv1DAQhS1URLelN87IRw6k2HFiJxekZVW2i6pWou2Km-U449Yosbe2U7T8Cn4yXlqqcuM0mvGnN2_8DtCe8w4QekPJMaVl8-HLenVMypKxgvIXaEZJ2xR1Tas9NCN5XtSs-baPDmL8TgitKl69QvtlQ0Vbl2KGfp2u1sXlBrQ1VuNlUO7ndgT8qbgEHSBZd4O7KeFzn_BSjaPCK5cgGAjePUOu8AKGIeJ5ADyP0WurEvT4h023-Cv0k87N2gY15C5CuPc2RGwdPlFh2OJsIcsa0Ml69xq9NGqIcPRYD9H155OrxWlxdrFcLeZnha6oSIXqeKW7RhjFhSmZ6LuKN60ieaBAATGdIdD3PTG8JAqAs64UtBGMN2WtFWeH6OOD7mbqRug1uJT9yU2wowpb6ZWV_744eytv_L2smag5J1ng3aNA8HcTxCRHG3X-BuXAT1HSpt3tY6L6D5Rz3lJOREbfP6A6-BgDmCdHlMhd3jLnLf_kLenuirfPr3iC_wbMfgNGoaoO |
CitedBy_id | crossref_primary_10_20411_pai_v6i2_447 crossref_primary_10_4049_jimmunol_2000916 crossref_primary_10_1016_j_ebiom_2023_104538 crossref_primary_10_3389_fimmu_2021_734871 crossref_primary_10_3390_ijms24109047 crossref_primary_10_3389_fimmu_2018_02429 crossref_primary_10_1128_JVI_01480_18 crossref_primary_10_3389_fimmu_2020_00153 crossref_primary_10_3390_v11121104 crossref_primary_10_3390_vaccines12040441 crossref_primary_10_1016_j_immuni_2020_10_015 crossref_primary_10_1128_JVI_01832_18 crossref_primary_10_1172_jci_insight_142640 crossref_primary_10_3389_fimmu_2018_02443 crossref_primary_10_1080_07853890_2021_1995624 crossref_primary_10_1097_QAI_0000000000001747 crossref_primary_10_1172_jci_insight_93684 crossref_primary_10_1016_j_xcrm_2021_100205 crossref_primary_10_1007_s11904_019_00445_6 crossref_primary_10_1128_jvi_00509_22 crossref_primary_10_1097_QAD_0000000000002296 crossref_primary_10_1002_eji_202048976 crossref_primary_10_1097_QAI_0000000000001887 |
Cites_doi | 10.1189/jlb.0208107 10.1016/j.immuni.2008.10.010 10.1016/S0022-1759(00)00191-5 10.1093/cid/cis188 10.1097/01.COH.0000209582.82328.b8 10.1186/1479-5876-1-14 10.1016/j.tim.2015.01.013 10.1016/j.coviro.2013.07.006 10.1073/pnas.1406663111 10.1073/pnas.0611244104 10.1073/pnas.95.15.8869 10.1038/ni845 10.1086/428777 10.1073/pnas.1414926112 10.1186/1742-4690-10-11 10.1126/scitranslmed.3003165 10.1073/pnas.1609057113 10.1101/cshperspect.a007054 10.1093/ofid/ofv138 10.1097/QAI.0b013e3182a1bc81 10.1016/j.cell.2013.09.020 10.1097/COH.0b013e32835d6e1c 10.1038/nm880 10.1016/S0140-6736(04)15735-8 10.1038/nri3839 10.1146/annurev-pathol-011110-130254 10.1128/JVI.01472-10 10.1101/cshperspect.a006916 10.1097/QAD.0000000000000508 10.1038/ncomms9495 10.1101/cshperspect.a007096 10.1128/jcm.32.3.732-739.1994 10.1073/pnas.96.26.15109 |
ContentType | Journal Article |
Copyright | Copyright © 2017 American Society for Microbiology. Copyright © 2017 American Society for Microbiology. 2017 American Society for Microbiology |
Copyright_xml | – notice: Copyright © 2017 American Society for Microbiology. – notice: Copyright © 2017 American Society for Microbiology. 2017 American Society for Microbiology |
DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 7T5 7U9 H94 5PM |
DOI | 10.1128/JVI.02233-16 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef MEDLINE - Academic Immunology Abstracts Virology and AIDS Abstracts AIDS and Cancer Research Abstracts PubMed Central (Full Participant titles) |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef MEDLINE - Academic AIDS and Cancer Research Abstracts Immunology Abstracts Virology and AIDS Abstracts |
DatabaseTitleList | MEDLINE - Academic CrossRef MEDLINE AIDS and Cancer Research Abstracts |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Biology |
DocumentTitleAlternate | Granzyme B and HIV Reservoirs |
EISSN | 1098-5514 |
Editor | Silvestri, Guido |
Editor_xml | – sequence: 1 givenname: Guido surname: Silvestri fullname: Silvestri, Guido |
ExternalDocumentID | 10_1128_JVI_02233_16 28179527 |
Genre | Journal Article |
GrantInformation_xml | – fundername: CIHR grantid: HOP-10754 – fundername: Ontario HIV Treatment Network (OHTN) grantid: AHRC G769 – fundername: Gouvernement du Canada | Canadian Institutes of Health Research (CIHR) grantid: HOP-10754 |
GroupedDBID | --- -~X 0R~ 18M 29L 2WC 39C 4.4 53G 5GY 5RE 5VS 85S ABPPZ ACGFO ACNCT ADBBV AENEX AGVNZ ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BTFSW CGR CS3 CUY CVF DIK E3Z EBS ECM EIF EJD F5P FRP GX1 H13 HYE HZ~ IH2 KQ8 N9A NPM O9- OK1 P2P RHF RHI RNS RPM RSF TR2 UCJ UPT W2D W8F WH7 WOQ YQT ~02 ~KM AAYXX CITATION 7X8 7T5 7U9 H94 5PM |
ID | FETCH-LOGICAL-c417t-ab64cb87fa67f237db4689a07faaeae0fbf0eddd0f620aee63b2718736825ca63 |
IEDL.DBID | RPM |
ISSN | 0022-538X |
IngestDate | Tue Sep 17 21:24:17 EDT 2024 Wed Jul 24 17:49:57 EDT 2024 Fri Aug 16 23:51:17 EDT 2024 Thu Sep 12 17:16:47 EDT 2024 Sat Sep 28 08:33:38 EDT 2024 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 8 |
Keywords | acute granzyme B viral reservoirs early HIV T cell cure research ELISpot IFN-γ HIV acute HIV human immunodeficiency virus CTL reservoir cytotoxic early |
Language | English |
License | Copyright © 2017 American Society for Microbiology. All Rights Reserved. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c417t-ab64cb87fa67f237db4689a07faaeae0fbf0eddd0f620aee63b2718736825ca63 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Citation Yue FY, Cohen JC, Ho M, Rahman AKMN, Liu J, Mujib S, Saiyed A, Hundal S, Khozin A, Bonner P, Liu D, Benko E, Kovacs C, Ostrowski M. 2017. HIV-specific granzyme B-secreting but not gamma interferon-secreting T cells are associated with reduced viral reservoirs in early HIV infection. J Virol 91:e02233-16. https://doi.org/10.1128/JVI.02233-16. F.Y.Y. and J.C.C. contributed equally to this article. |
OpenAccessLink | https://jvi.asm.org/content/jvi/91/8/e02233-16.full.pdf |
PMID | 28179527 |
PQID | 1866691607 |
PQPubID | 23479 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_5375660 proquest_miscellaneous_1891873374 proquest_miscellaneous_1866691607 crossref_primary_10_1128_JVI_02233_16 pubmed_primary_28179527 |
PublicationCentury | 2000 |
PublicationDate | 2017-04-15 |
PublicationDateYYYYMMDD | 2017-04-15 |
PublicationDate_xml | – month: 04 year: 2017 text: 2017-04-15 day: 15 |
PublicationDecade | 2010 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States – name: 1752 N St., N.W., Washington, DC |
PublicationTitle | Journal of virology |
PublicationTitleAlternate | J Virol |
PublicationYear | 2017 |
Publisher | American Society for Microbiology |
Publisher_xml | – name: American Society for Microbiology |
References | e_1_3_2_26_2 e_1_3_2_27_2 e_1_3_2_28_2 e_1_3_2_29_2 e_1_3_2_20_2 e_1_3_2_21_2 e_1_3_2_22_2 e_1_3_2_23_2 e_1_3_2_24_2 e_1_3_2_25_2 e_1_3_2_9_2 e_1_3_2_15_2 e_1_3_2_8_2 e_1_3_2_16_2 e_1_3_2_7_2 e_1_3_2_17_2 e_1_3_2_6_2 e_1_3_2_18_2 e_1_3_2_19_2 e_1_3_2_30_2 e_1_3_2_32_2 e_1_3_2_10_2 e_1_3_2_31_2 e_1_3_2_5_2 e_1_3_2_11_2 e_1_3_2_34_2 e_1_3_2_4_2 e_1_3_2_12_2 e_1_3_2_33_2 e_1_3_2_3_2 e_1_3_2_13_2 e_1_3_2_2_2 e_1_3_2_14_2 |
References_xml | – ident: e_1_3_2_24_2 doi: 10.1189/jlb.0208107 – ident: e_1_3_2_15_2 doi: 10.1016/j.immuni.2008.10.010 – ident: e_1_3_2_30_2 doi: 10.1016/S0022-1759(00)00191-5 – ident: e_1_3_2_12_2 doi: 10.1093/cid/cis188 – ident: e_1_3_2_27_2 doi: 10.1097/01.COH.0000209582.82328.b8 – ident: e_1_3_2_31_2 doi: 10.1186/1479-5876-1-14 – ident: e_1_3_2_9_2 doi: 10.1016/j.tim.2015.01.013 – ident: e_1_3_2_7_2 doi: 10.1016/j.coviro.2013.07.006 – ident: e_1_3_2_28_2 doi: 10.1073/pnas.1406663111 – ident: e_1_3_2_16_2 doi: 10.1073/pnas.0611244104 – ident: e_1_3_2_2_2 doi: 10.1073/pnas.95.15.8869 – ident: e_1_3_2_18_2 doi: 10.1038/ni845 – ident: e_1_3_2_5_2 doi: 10.1086/428777 – ident: e_1_3_2_26_2 doi: 10.1073/pnas.1414926112 – ident: e_1_3_2_3_2 doi: 10.1186/1742-4690-10-11 – ident: e_1_3_2_29_2 doi: 10.1126/scitranslmed.3003165 – ident: e_1_3_2_33_2 doi: 10.1073/pnas.1609057113 – ident: e_1_3_2_23_2 doi: 10.1101/cshperspect.a007054 – ident: e_1_3_2_19_2 doi: 10.1093/ofid/ofv138 – ident: e_1_3_2_11_2 doi: 10.1097/QAI.0b013e3182a1bc81 – ident: e_1_3_2_8_2 doi: 10.1016/j.cell.2013.09.020 – ident: e_1_3_2_22_2 doi: 10.1097/COH.0b013e32835d6e1c – ident: e_1_3_2_4_2 doi: 10.1038/nm880 – ident: e_1_3_2_13_2 doi: 10.1016/S0140-6736(04)15735-8 – ident: e_1_3_2_17_2 doi: 10.1038/nri3839 – ident: e_1_3_2_6_2 doi: 10.1146/annurev-pathol-011110-130254 – ident: e_1_3_2_20_2 doi: 10.1128/JVI.01472-10 – ident: e_1_3_2_32_2 doi: 10.1101/cshperspect.a006916 – ident: e_1_3_2_21_2 doi: 10.1097/QAD.0000000000000508 – ident: e_1_3_2_14_2 doi: 10.1038/ncomms9495 – ident: e_1_3_2_10_2 doi: 10.1101/cshperspect.a007096 – ident: e_1_3_2_34_2 doi: 10.1128/jcm.32.3.732-739.1994 – ident: e_1_3_2_25_2 doi: 10.1073/pnas.96.26.15109 |
SSID | ssj0014464 |
Score | 2.4187756 |
Snippet | A major barrier to a human immunodeficiency virus type 1 (HIV-1) infection cure is the establishment of a viral reservoir in spite of combined antiretroviral... ABSTRACT A major barrier to a human immunodeficiency virus type 1 (HIV-1) infection cure is the establishment of a viral reservoir in spite of combined... |
SourceID | pubmedcentral proquest crossref pubmed |
SourceType | Open Access Repository Aggregation Database Index Database |
SubjectTerms | Adult Antiviral Agents CD4-Positive T-Lymphocytes - virology CD8-Positive T-Lymphocytes - immunology CD8-Positive T-Lymphocytes - metabolism CD8-Positive T-Lymphocytes - virology Cytotoxins - metabolism Disease Reservoirs - virology Granzymes - metabolism HIV Infections - immunology Human immunodeficiency virus 1 Humans Interferon-gamma - metabolism Lentivirus Male Middle Aged Pathogenesis and Immunity Retroviridae Young Adult |
Title | HIV-Specific Granzyme B-Secreting but Not Gamma Interferon-Secreting T Cells Are Associated with Reduced Viral Reservoirs in Early HIV Infection |
URI | https://www.ncbi.nlm.nih.gov/pubmed/28179527 https://search.proquest.com/docview/1866691607 https://search.proquest.com/docview/1891873374 https://pubmed.ncbi.nlm.nih.gov/PMC5375660 |
Volume | 91 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1da9swFBVtYbCXsXZf2bqhwfaoxJYsyX7cwtq0sDK2NuTNSLZEDbFcEmfQ_Yr95F3JUUk72MMeLV9bwufaulc6PhehD4lWSkCaQIwwjEAEnhANUTHhNjNGpEJJG1i-F2J2lZ0v-GIP8fgvTCDtV7oZu2U7ds114FbetNUk8sQm375OOZMQhSSTfbQvGYsp-nbrAPKbLEqEw9u8iGx3mk_O52djaGaMpL50Ec3BG7mvJ7M7Jf0VZz6kS-7MPydP0ZNt4Ig_DQM8RHvGHaFHQynJ22fo9-xsTkIxedtU-BRmoF-3rcGfyQ8fF3puM9abHl90PT5VbatwWAq0ZtW5HZNLPDXL5Rp6MTgCZ2rsF2vxdy_yCgfzBkaHPWNv9bNrVmvcOBxkkjEMAW47kLvcc3R18uVyOiPbagukylLZE6VFVulcWsDOUiZrnYm8UAk0KKNMYrVNTF3XiRU0UQAk0xQmNskEJJmVEuwFOnCdM68Qhu9EqjgXKisgvaFK0ULVvFYCzAzkeCP0MT7w8mYQ1ShDMkLzEjAqA0ZlKkbofUSjBK_3WxnKmW6zLr1Mnyi8ON6_bAo_PCazEXo5IHjXW4R-hOQ9bO8MvOr2_TPgjEF9e-t8r__7yjfoMfWxgReM5MfooF9tzFuIbHr9LnjyH4An-c0 |
link.rule.ids | 230,315,733,786,790,891,27955,27956,53825,53827 |
linkProvider | National Library of Medicine |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9MwED-NIQQvfH-UTyPBo9PEiZ3kESq2dmwVgq7qW2QnjohokqlNkba_gj-Zs1NP3ZCQ4DH2JbF159yd_cvvAN75SkqBaQLVQocUI3CfKoyKKS8jrUUgZFxalO9UjE-jowVf7AF3_8JY0H6uKq9Z1l5TfbfYyrM6Hzqc2PDLyYiHMUYh_vAG3MT1yrhL0reHB5jhRI4kHPsXDu_OkuHRfOJhcxjSwBQvYgnaIzcVZXad0h-R5nXA5I4HOrgHczf2Hnjyw9t0yssvrtE6_vPk7sPdbUxKPvTdD2BPNw_hVl-l8vwR_BpP5tTWqS-rnByic7s4rzX5SL-ZkNPAponadGTaduRQ1rUkdpex1Ku22RGZkZFeLtf4Fk2cTeiCmH1g8tXwx-LFvMJpEwMGXP1sq9WaVA2xDMwEh4CP7XFjzWM4Pfg0G43ptpADzaMg7qhUIspVEpdoFiUL40JFIkmljw1SS-2XqvR1URR-KZgv0UZCxdBnxqFA5eZShE9gv2kb_QwIfoICybmQUYqZE5OSpbLghRQopjF9HMB7p8nsrOfryGyew5IMlZ9Z5WeBGMBbp-YMF5Q5JZGNbjfrzDAAitTw7v1NJjXDC-NoAE9707h8m7OpAcRXjOZSwBB6X-1BU7DE3lvVP__vO9_A7fHs5Dg7nkw_v4A7zIQghpeSv4T9brXRrzCA6tRru1x-A6SIG9I |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFLZgCMQL90u5GgkenYudOMkjFLp2QDXBVlW8RHZia9GapGpTpO1X8JM5duqpGxIPe4x9Etvy5_gc-9N3EHofSCE4hAlEccUIeOABkeAVk1hHSvGQi0Rblu-Uj4-jg3k830n1ZUn7hay8ZlF7TXViuZXLuvAdT8w__D6MWQJeSOAvS-3fRLdgzdLEBerbCwSIciInFA71c8d5p6l_MJt4UMwYCU0CI5oCJmOTVWZ3Y_rH27xKmtzZhUb30S_X_558cuptOukV51ekHa81wAfo3tY3xR97k4fohmoeodt9tsqzx-jPeDIjNl-9rgq8D5vc-Vmt8Cfy07iehj6N5abD07bD-6KuBbanjVqt2mbH5AgP1WKxhlYUdthQJTbnwfiH0ZGFh1kFQ8eGFLj63VarNa4abJWYMXQBPtvzx5on6Hj05Wg4JtuEDqSIwqQjQvKokGmiAR6asqSUEU8zEUCBUEIFWupAlWUZaE4DAVhhksLemTAOcWwhOHuK9pq2Uc8Rhl9RKOKYiyiDCIoKQTNRxqXgYKYgjBygD24282Wv25HbeIemOQAgtwDIQz5A79xU57CwzG2JaFS7WedGCZBnRn_vfzaZ6R5LogF61sPjojWHqwFKLgHnwsAIe1-uAThYge_t9L-49ptv0Z3Dz6P822T69SW6S40nYuQp41dor1tt1Gvwozr5xq6Yv3lnHlI |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=HIV-Specific+Granzyme+B-Secreting+but+Not+Gamma+Interferon-Secreting+T+Cells+Are+Associated+with+Reduced+Viral+Reservoirs+in+Early+HIV+Infection&rft.jtitle=Journal+of+virology&rft.au=Yue%2C+Feng+Yun&rft.au=Cohen%2C+Jared+C&rft.au=Ho%2C+Mu&rft.au=Rahman%2C+A+K+M+Nur-Ur&rft.date=2017-04-15&rft.eissn=1098-5514&rft.volume=91&rft.issue=8&rft_id=info:doi/10.1128%2FJVI.02233-16&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0022-538X&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0022-538X&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0022-538X&client=summon |